The prognostic value of the tumor-stroma ratio in squamous cell lung cancer, a cohort study
Autor: | Pieter E. Postmus, Marloes A Smit, Wilma E. Mesker, Danielle Cohen, Mark Wh Philipsen, Rob A. E. M. Tollenaar, Hein Putter |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Oncology Male Cancer Research medicine.medical_specialty Lung Neoplasms H&E stain NSCLC Cohort Studies 03 medical and health sciences 0302 clinical medicine Squamous cell carcinoma Internal medicine Pathology medicine Humans Stage (cooking) Lung cancer RC254-282 Survival analysis Aged Neoplasm Staging Retrospective Studies Aged 80 and over Lung Tumor-stroma ratio business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens Middle Aged medicine.disease Prognosis Primary tumor 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Cohort Carcinoma Squamous Cell Female business Cohort study |
Zdroj: | Cancer Treatment and Research Communications, Vol 25, Iss, Pp 100247-(2020) |
ISSN: | 2468-2942 |
Popis: | Objectives The tumor-stroma ratio (TSR) is based on the relative amount of stroma in the primary tumor and has proven to be an independent prognostic factor in various solid tumors. The prognosis of patients and adjuvant treatment decision making in lung squamous cell carcinomas (SqCC) is based on the TNM classification. Currently, no other prognostic biomarkers are available. In this study we evaluated the prognostic value of the TSR in lung SqCC. Material and Methods Patients undergoing lung surgery because of lung SqCC between 2000 and 2018 at the Leiden University Medical Center were included. The TSR was scored on hematoxylin & eosin stained tissue sections. Based on the amount of tumor-stroma, two groups were defined: ≤50% was classified as a stroma-low tumor and >50% as stroma-high. The prognostic value of the TSR was determined with survival analysis. Results A total of 174 stage I-III patients were included. Of them, 79 (45%) were stroma-low and 95 (55%) stroma-high. Separately analyzed for tumor stages, the TSR showed to be an independent prognostic biomarker in stage II (n = 68) for 5-year overall survival (HR=3.0; 95% CI, 1.1–8.6; p = 0.035) and 5-year disease free survival (DFS) (HR=3.6; 95% CI, 1.3–9.9; p = 0.014). Patients with a stroma-high tumor had a worse 5-year DFS in the whole cohort (HR 1.6; 95% CI, 1.0–2.4; p = 0.048), but no independent prognostic value was found. Conclusion In stage II lung SqCC patients, stroma-low tumors have a better prognosis compared to stroma-high tumors. Moreover, adjuvant chemotherapy could be spared for these stroma-low patients. |
Databáze: | OpenAIRE |
Externí odkaz: |